Rein Therapeutics Inc. (RNTX)
Rein Therapeutics Statistics
Share Statistics
Rein Therapeutics has 21.99M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 21.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 270 |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 156.09K, so 0.72% of the outstanding shares have been sold short.
| Short Interest | 156.09K |
| Short % of Shares Out | 0.72% |
| Short % of Float | 0.72% |
| Short Ratio (days to cover) | 4.92 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Rein Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rein Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.
| Current Ratio | 2.38 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-5.72M |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | 2.4% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 2.12, so Rein Therapeutics's price volatility has been higher than the market average.
| Beta | 2.12 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 46.29 |
| Average Volume (20 Days) | 38.77K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -65.11M |
| Net Income | -62.88M |
| EBITDA | -28.05M |
| EBIT | -28.11M |
| Earnings Per Share (EPS) | -3.51 |
Balance Sheet
The company has 12.87M in cash and 0 in debt, giving a net cash position of 12.87M.
| Cash & Cash Equivalents | 12.87M |
| Total Debt | 0 |
| Net Cash | 12.87M |
| Retained Earnings | -351.4M |
| Total Assets | 62.19M |
| Working Capital | 7.91M |
Cash Flow
In the last 12 months, operating cash flow was -22.29M and capital expenditures 0, giving a free cash flow of -22.29M.
| Operating Cash Flow | -22.29M |
| Capital Expenditures | 0 |
| Free Cash Flow | -22.29M |
| FCF Per Share | -1242.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for RNTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Nov 11, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 11, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -7.63 |
| Piotroski F-Score | 1 |